[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

MP Advisors: Market Research Reports

MP Advisors is an independent company offering research and paramount knowledge within a healthcare industry. At present great many global pharmaceutical companies, especially in U.S., Europe, Russia, India and Japan are among MP Advisors’s clients. When founded, 1996, the agency is ensuring investment solutions and assessing investment opportunities with a penetrating eye on risks and benefits from funding pharma manufacturing.

MP Advisors unparalleled service includes:

  • Financial Analysis;
  • Competitive landscaping;
  • Macro Analysis;
  • Technology Transfer;
  • Mergers & Acquisitions;
  • Strategic planning;
  • Forecast.

Customized reports are in the focus area of skillful and competent experts who explore, analyze and interpret data, select tools and approaches on how efficiently reach ultimate market decisions and reach maximum understanding of current biotech and therapeutic issues.

More than 200 medical companies’ profiles are in its database. MP Advisors publishes insightful reports fortified by proficient views of key specialists. Moreover, it produces ad hoc reports on Japan and Indian generic drug, Para IV, oncology, obesity and other therapy reviews.

Publications found: 456
Sort by:
Outlook of Diabetic Macular Edema – Current Landscape and the Way Forward US$ 4,500.00


June 2020 81 pages
Japan Biosimilars- Landscape Today Outlook Tomorrow US$ 4,500.00

“Biosame” entry, uninterrupted supply and companies’ strong front-end footprint requirement makes it distinctAfter a decade, JP Biosimilar guideline’s first revision expected in FY2020 –Demonstrate Ch...

January 2020 156 pages
BIOCON, Growth Drivers - Long Term and Uncertain, Expenses - Near Term and Certain US$ 140.00

Q3FY13 result of Biocon was moderately better than our estimates. Revenue of ... in Simvastatin. As per the company, biosimilars seem to be the biggest growth drivers in the longer term; however we do not see any visibility as of ... unreported licensing income) at 1x. We retain our Market Perform rating on Biocon.

December 2017 7 pages
Next Decade Generic String Of Pearls Opportunities: Sustainability Assessment With Respect To Therapeutic Positioning US$ 4,000.00

... prospective generic drug product comprises of product (Active Pharmaceutical Ingredient-API) selection and identification. API is the primary ... classes covered in this report are: Oncology Cardiovascular Respiratory Gastroenterology Psychiatry Infectious disease The following points were considered while ...

November 2017 127 pages
The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis US$ 4,000.00

... with systemic agents. Driven by improved efficacy, the first group of anti TNF treatments led by Enbrel, Humira and Remicade made strong penetration into the psoriasis market. However the emergence of the IL-17 inhibitor class ...

October 2017 104 pages
Japan Biosimilars – A start of Authorized Biosimilar Era? Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market! US$ 4,000.00

... ~4000) and early entry of the player are critical factors to decide biosimilar penetration and market share dynamics of Japan Biosimilar Market. While ... in next few years for Japan biosimilar players. In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive landscape, ...

August 2017 128 pages
Prostate Cancer - Newer Antiandrogens & Emerging Therapies Targeting a “Watchful Waiting” and Resistance Population US$ 4,500.00

... Stage Prostate Cancer Pipeline drugs – AKT inhibitors or PARP inhibitors or a new MoA combination with Antiandrogen or IO combo - Competing to Xtandi/Zytiga or targeting Xtandi/Zytiga Resistance Population? Increase in prevalence of Prostate cancer and availability of new treatment options (Zytiga, Xtandi ...

January 2017 200 pages
Pain Management- New Discoveries and Treatment Options in Abuse Deterrent Era US$ 3,500.00

... management of pain. Late stage NCE pipeline drugs (Cebranopadol, Mirogabalin, NKT-181, AVP-923,…) and Novel technologies targeting formulation change in old generic drugs (ORB-201, OX-51, ARX-04,CL-108, once daily Pregabalin..) for pain management has potential to reduce opioids ...

August 2016 135 pages
India Pharma Outlook 2016: Milestones to Watch – Growth from Exports and Domestic Getting Better, Implementation of Policies under “Make-in-India”, Overture of A New Ministry US$ 1,500.00

... Lupin, Cipla, Sun pharma) and sustainable growth from Domestic formulation (e.g. Alkem, Cipla, Sun pharma, Dr Reddy), mainly from Chronic diseases’ segment, due to growth ... explore further opportunities of growth, Indian pharma companies have started developing complex generics/biosimilars. Almost all companies ...

March 2016 35 pages
Large CAP Pharma US & EU Outlook 2016: Maximizing Their Strength on Fewer Therapy Class, Personalized Medicine, Novel Target and Biosimilars for Future Growth US$ 2,000.00

... to develop drugs for specialty medicine (Multiple Sclerosis, Inflammatory Bowel Disease), Neurodegeneration (Alzheimer’s disease, Parkinson’s, ALS, Neuro-immunology) and rare diseases (Hemophilia, Spinal Muscular Atrophy and Neuropathic Pain). Celgene (CELG ...

March 2016 97 pages
Japan Pharma Outlook 2016: JP Giants leaning in for becoming a Speciality Global Pharma US$ 2,500.00

... , Edoxaban uptake in EU, Alectinib uptake in US and ACE-910 approval for hemophilia will decide Japanese Innovator growth in Global market. The biennial price cut scheduled in April-2016 ...

March 2016 91 pages
Rising Stars Outlook 2016: New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH) US$ 2,000.00

Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies ...

January 2016 56 pages
Japan Biosimilar- Active Players In Quest of a Specialty & Niche BS space US$ 4,000.00

... , Filgrastim/Pegfilgrastim/ Insulin/Lantus apart from other key complex Mab Biosimilar opportunities and list out niche opportunities in biosimilar space in Japan. It details all major consolidation activities ...

December 2015 101 pages
Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies US$ 3,500.00

... guidelines for the clinical trial in CY16 and this should accelerate the development of the drugs targeting NASH. NASH is the progressive form of Non-Alcoholic Fatty Liver Disease – NAFLD. While NASH can reverse itself ...

November 2015 65 pages
Buccal Drug Delivery Systems: Opportunities and Challenges in Buccal, Sublingual Films, Tablets & Sprays – Detailed Analysis on Technologies and Pipeline Development US$ 3,000.00

... as Biodelivery Sciences, Bioalliance pharma (Onexo), Meda pharma, Orexo, Generex, Teijin are actively involved in developing oral mucoadhesive buccal delivery systems while sublingual technology have been used by Teva, Sun pharma, Grunenthal, Neurax, Angelini, Sandoz, Ethypharm, Arrow generics, Purdue and ...

October 2015 70 pages
India Pharma Outlook 2015: Accelerating Growth to the Next Level: Moving up the Value Chain Beyond Generics US$ 2,000.00

... of NCE/mAb development by Indian companies is a sign of Indian Generics moving up in the chain. Biopharma/ biotech companies in India, S. Korea, China may have significant advantages of low-cost manufacturing ...

February 2015 109 pages
Japan Pharma Outlook 2015: 2015 –Year to Watch Out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives US$ 2,000.00

... pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies - whether generic ... Outlook-15, we look deeper into these trends to anticipate likely near term changes of Japanese pharma ... Edoxaban, Lenvatinib, Entyvio, Brintellix, and Ixazomib are the few ...

January 2015 153 pages
Global Pharma US & EU Outlook 2015: First –In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies US$ 2,000.00

... diabetes (SGLT-2, GLP-1 agonists), Multiple Sclerosis, HCV, melanoma and breast cancer from major ... anti-PD1, anti-PCSK9 and CDK inhibitors have also got exclusive attention by large cap Pharma ... business among major pharma including Vaccines, OTC and animal health to improve margins. Global Pharma continues to ...

January 2015 63 pages
Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success US$ 2,000.00

All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been ...

January 2015 90 pages
Sri Lanka Pharma Market Outlook 2015: More Beyond Importers & Distributors US$ 2,000.00

... the healthcare needs of the country. Sri Lanka’s total expenditure on health has increased by ~11%, CAGR (2005-2010), and this has been driven by both private- (+12%) and government ...

January 2015 29 pages
New Phase of Mab biosimilar knocks the door Biosimilar Opportunities In Japan US$ 4,000.00

... players (Daiichi-Sankyo, KHK), JP Innovator+ GE companies (Meiji, Fujifilm, Nippon Kayaku, Mochida, and Kissei), Global Multinationals (Pfizer, Sandoz) and some rising star JP local companies (Yoshindo, Gene Techno Science, Sanwa Kagaku ...

January 2015 65 pages
Dietary Supplements: World of Opportunities In the Indian Healthcare Market US$ 2,000.00

... new opportunities or geography expansion in the functional food, beverage, and supplement (FBS) market. Nutraceutical is divided into three segments – dietary supplements, functional foods and functional beverages. Globally, Nutraceuticals ...

January 2015 62 pages
Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure US$ 3,000.00

... with aging (dementia, Alzheimer's etc.) are on the rise!. Consequently the pharma industry continues to grow and is projected ... the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic have reached a critical mass warranting a ...

January 2015 98 pages
Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease US$ 3,000.00

... Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need – POMALYST/ IMNOVID (pomalidomide – POM, Celgene, approved) and Kyprolis (carfilzomib ...

January 2015 82 pages
Global Rising Stars Outlook 2015: Innovative Therapies for Treating Diseases are Being Sought after with Fresh Vigor as New Targets US$ 2,000.00

Innovative Therapies for treating diseases ... interested in keeping pace with the development of new medicines. The Regenerative medicine Universe is large and new companies are being ... coverage in our Outlook this year. Key Criteria for Our Selection are:- Uniqueness of the Technology platform and the ability ...

January 2015 72 pages
India Rising Stars Outlook 2015: Traditionally Innovation and Drug Discovery Had Taken a Back Seat in the Indian Pharma Industry with a Few Blips Here and There US$ 1,000.00

Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there. ... 2-3 years thereby rewarding their investors. . In this Outlook we have initiated coverage on Connexios, Bugworks, Cellworks, Tergene and hope that soon we will be able to expand ...

January 2015 22 pages
Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain US$ 3,000.00

... cyclooxygenase (COX) inhibitors, amine reuptake inhibitors and anticonvulsants, ... acute and chronic moderate to severe pain. Globally, pain is one of the ... formulations can be better understood from FDA’s non-approval of oxycontin generics in 2013. The revised labeling with abuse deterrence has protected Purdue ...

January 2015 65 pages
Therapeutic Class Overview: Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain US$ 3,000.00

... of novel delivery technologies employed in the formulation of abuse deterrent product, technologies employed in enhancing patient compliances and emerging novel mechanisms in the management of pain. Renewed interest on pain therapy ...

December 2014 64 pages
Innovative Drug Delivery Systems Opportunities For Generic & Specialty Pharmaceutical Companies US$ 2,500.00

There are more than 1400 sustained or controlled release drugs have been approved all over the world. Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of generics is approximately 20% of overall ...

February 2014 91 pages
Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral Drugs and Biologics to Change Future Treatment Paradigm US$ 2,500.00

Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded ... OTEZLA – apremilast, Xeljanz – tofacitinib) and onwards. In this report, we highlight the novel targets – oral, injectables, and topical drugs in the pipeline for the treatment of Psoriasis ...

February 2014 55 pages
Therapeutic Class Overview: Treating Refractory Hematological Malignancies US$ 2,500.00

... decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs – Thalomid (thalidomide) and Revlimid (lenalidomide) have become the cornerstone of treatment for patients with Multiple Myeloma (MM) resulting ...

February 2014 43 pages
Therapeutic Class Overview: Emergence of Biogenerics Era in Japan - it's time to welcome Antibody Biosimilars of Foreign Origins Soon US$ 2,500.00

... map for biosimilars space, at this time we see Sandoz, JCR, Meiji Seika Pharma, Fuji Film Kyowa Kirin Biologics, Nippon Kayaku, Nichi Iko, Yoshindo etc. to be amongst the key players in biogenerics business in Japan. It is also noteworthy ...

February 2014 31 pages
Therapeutic Class Overview: New avatars of microbes super bugs a growing threat worldwide US$ 1,500.00

... infections during the treatment were not available. If that fails, the gains ... super infections” warranting need for new classes of antibiotics and other preventive/therapeutic approaches ... Gram Negative infections and CRE. Pipeline of novel targets being used to develop new drugs to treat infections and resistance ...

February 2014 12 pages
Therapeutic Class Overview: Newer Oral Anti Androgens – Expanding Role in The Treatment Paradigm of Prostate Cancer US$ 2,500.00

... bigger for newer options than late stage if they succeed.In coming years, we expect second generation antiandrogens (Androgen synthesis inhibitors/Androgen receptor inhibitors, Xtandi, ARN-509, ODM-021, Zytiga, TAK-700, TOK-001) to replace ...

February 2014 44 pages
Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars US$ 2,500.00

... in drug approvals, upcoming milestones and M&A in coming years please see Global Pharmaceutical and Biotechnology Outlook 2013: Rising Stars

January 2014 113 pages
Global Pharmaceutical and Biotechnology Outlook 2014 - India Pharma US$ 2,500.00

... by pharma companies in India. Our outlook 2014 on India Pharma covers overall business and market growth for Indian companies, ParaIV filing, NCE pipeline and biosimilar and NDDS development ...

January 2014 66 pages
Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma US$ 2,500.00

... : NHI price cut, Japan generic opportunity, Prograf, Xtandi, Isavuconazole, Myrbetriq, Astellas, Chugai, Actemra, Perjeta, biosimilar, Kadcyla, breast cancer, prostate cancer, MPDL3280A, Daiichi Sankyo, Edoxaban , Ranbaxy, Dainnipon Sumitomo, Dainnipon, cancer stem cell inhibitor, BBI-608, Latuda, DS-3025 ...

January 2014 141 pages
DAINIPPON SUMITOMO PHARMA - Expectation From BBI-608 To Achieve FY2017 MTP Target Looks Unachievable! US$ 500.00

... Cancer Stem Cell Inhibitors- from OncoMed/Celgene (OMP-21M18, OMP-52M51) And Bionomics (BNC-101) also need a close watch. On M & A front (Table 11), DSP’s R & D collaboration with Edison pharma ...

January 2014 14 pages
TAKEDA , Challenges Ahead for its New European Presiden US$ 500.00

... failure a moderate Positive- while development of Brexpiprazole looks a close competitor!.........Vedolizumab (MLN0002, UR, US/EU, vedolizumab, α4β7 integrin inhibitor, Ulcerative colitis / Crohn’s disease) and MLN-9708 (PhIII, Multiple Myeloma) are the most promising late ...

January 2014 24 pages
Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU US$ 2,500.00

... melanoma and breast cancer from major pharmaceutical companies. Many of them are ... high premium in speculation of getting acquired (ex. Roche-Alexion). Going forward, Economies of Scale will ... repurchase program and dividend policy. Global Biopharmaceutical Outlook 2014-Global Pharma, released by MP Advisors ...

January 2014 113 pages
Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech US$ 2,500.00

... : Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron, Vertex, ACOR, ALXN, AMGN, BIIB, CELG, GILD, REGN, VRTX, Soliris, Eculizumab, Asfotase alfa, Onyx, Kyprolis, RRMM, Denosumab, Prolia, XGEVA, Enbrel, Neupogen/ Neulasta, Biosimilar, Ampyra, Multiple Sclerosis, TECFIDERA, BG-12, PLEGRIDY, Gazyva ...

January 2014 145 pages
Enanta- It is just the beginning of good news US$ 90.00

... SVR12 data of SAPPHIRE-I –oral regimen (ENTA’s /ABT-450 boosted Abbvie’s ritonavir, ... data from the first of six Phase III HCV trial of ENTA/AbbVie's using its oral IFN free regimen. ... 1) and regulatory filing in 2nd half of 2014 we expect ENTA shares to appreciate further. We are positive on the PhIII study ...

November 2013 2 pages
Regeneron - Eylea’s Growth Potential and Pipeline is Lucrative Enough! US$ 140.00

... of Eylea (aflibercept, VEGF-Trap Eye, L, wet-AMD, Central Retinal Vein Occlusion – CRVO, partnered with Bayer for ex-US) in Diabetic Macular Edema (DME) and myopic choroidal neovascularization (mCNV) and promise of the late-stage pipeline esp. anti-PCSK9 mAb, Alirocumab (REGN727, PhIII, Hypercholesterolemia ...

October 2013 7 pages
Therapy Class Overview : Hepatitis C Virus Infection US$ 1,000.00

... Oral IFN –Free combinations for Treatment of HCV and ROW opportunity Competitive Landscape - IFN-Free drugs HCV Vaccines and their progress Difficult to treat and drugs for HCV-HIV co infection Market ...

October 2013 33 pages
Therapy Class Overview: Rituximab biosimilar US$ 2,000.00

... emerging market experience in India and Mexico. Rituximab biosililar pipeline, and the current status of clinical development What are the Innovator's strategy in protecting rituximab franchise? Competition to biosimilar rituximab ...

October 2013 45 pages
GALAPAGOS - Strengthening ties with AbbVie – RA and Cystic Fibrosis + Partnerships of Novel Targets Opportunity Remains US$ 90.00

... selective JAK1 inhibition by GLPG0634. For more detail, please read our report on GLPG, released on Oct. 4, 2013, titled, 'Strengthening ties with AbbVie – RA and Cystic Fibrosis + Partnerships of Novel Targets Opportunity ...

October 2013 3 pages
ABLYNX - Nanobodies - Turnarond on the Horizon! US$ 140.00

... of ALX-0061 (PhI/II, Anti-IL6R, RA) with AbbVie under attractive terms (deal value of $840m/~€630m) and news flow in last one year brought back Ablynx (ABLX ... ) and its nanobody platform’s’ potential in the limelight! Though ABLX suffered from several setbacks in 2011, ...

October 2013 7 pages
Incyte- INCB39110 – Another JAK-Fruit in INCY’s Basket US$ 140.00

... RA – Xeljanz) and in light of current competition in plaque psoriasis market. For more detail, please read our report on INCY, released on Oct. 3, 2013, titled, 'INCB39110 – Another JAK-Fruit in INCY ...

October 2013 5 pages
Merck Update: HCV combo, Lambrolizumab and Corporate Restructuring Program US$ 90.00

Merck announced restructuring (cost efficiency) program which is likely to ... by 2015) announced by the Company through workforce reduction across all functional divisions, head quarter relocation, out ... . More focused attention on therapy areas where Merck has proven its abilities irrespective of unmet need ...

October 2013 3 pages
MEDIVIR - Simeprevir- Good with and without IFN Combinations! US$ 140.00

... Simeprevir/IFN/RBV combination (TMC435, once daily Protease Inhibitor, PI, R, HCV, partnered with Tibotec/JNJ) in Japan and progress in IFN free combinations with various drugs has helped Medivir ... Though Gilead’s Sofosbuvir/IFN/RBV is not far behind, the real competition is for IFN free combinations and MVIR ...

September 2013 3 pages